SZSE:300233 (China)
Â
Class A
Â¥
19.95
-1.53 (-7.12%)
Mar 27
What is a stock summary page? Click here for an overview.
Business Description
Shandong Jincheng Pharmaceutical Group Co Ltd
NAICS : 325998
SIC : 2899
ISIN : CNE100001500
Share Class Description:
SZSE:300233: Class ACompare
Compare
Traded in other countries / regions
300233.China IPO Date
2011-06-22Description
Shandong Jincheng Pharmaceutical Group Co Ltd is engaged in the research and development, production and sale of III and IV cephalosporin intermediates and biopharmaceuticals. It offers characteristic bulk drugs, pharmaceutical intermediates, and fine chemicals. The company distributes its products within domestic market and to overseas markets.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.58 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | 2.24 | |||||
| Interest Coverage | 14.01 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.56 | |||||
| Beneish M-Score | -2.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.1 | |||||
| 3-Year FCF Growth Rate | 5.5 | |||||
| 3-Year Book Growth Rate | 3.3 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.49 | |||||
| 9-Day RSI | 60.47 | |||||
| 14-Day RSI | 62.86 | |||||
| 3-1 Month Momentum % | 7.42 | |||||
| 6-1 Month Momentum % | 7.59 | |||||
| 12-1 Month Momentum % | -13.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.65 | |||||
| Quick Ratio | 1.2 | |||||
| Cash Ratio | 0.7 | |||||
| Days Inventory | 95.99 | |||||
| Days Sales Outstanding | 57.41 | |||||
| Days Payable | 126.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.4 | |||||
| Dividend Payout Ratio | 0.51 | |||||
| 3-Year Dividend Growth Rate | -9.1 | |||||
| Forward Dividend Yield % | 1.4 | |||||
| 5-Year Yield-on-Cost % | 1.1 | |||||
| 3-Year Average Share Buyback Ratio | 0.7 | |||||
| Shareholder Yield % | 2.68 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 42.16 | |||||
| Operating Margin % | 8.15 | |||||
| Net Margin % | 5.55 | |||||
| FCF Margin % | 4.08 | |||||
| ROE % | 5.21 | |||||
| ROA % | 3.32 | |||||
| ROIC % | 6.35 | |||||
| 3-Year ROIIC % | -31.73 | |||||
| ROC (Joel Greenblatt) % | 10.91 | |||||
| ROCE % | 6.16 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 39.12 | |||||
| PE Ratio without NRI | 33.59 | |||||
| Shiller PE Ratio | 45.34 | |||||
| PS Ratio | 2.14 | |||||
| PB Ratio | 2.07 | |||||
| Price-to-Tangible-Book | 2.61 | |||||
| Price-to-Free-Cash-Flow | 54.79 | |||||
| Price-to-Operating-Cash-Flow | 18.91 | |||||
| EV-to-EBIT | 29.9 | |||||
| EV-to-EBITDA | 29.9 | |||||
| EV-to-Revenue | 2.28 | |||||
| EV-to-FCF | 49.34 | |||||
| Price-to-GF-Value | 0.93 | |||||
| Price-to-Projected-FCF | 1.68 | |||||
| Price-to-Median-PS-Value | 0.72 | |||||
| Price-to-Graham-Number | 1.98 | |||||
| Price-to-Net-Current-Asset-Value | 24.94 | |||||
| Earnings Yield (Greenblatt) % | 3.34 | |||||
| FCF Yield % | 1.86 | |||||
| Forward Rate of Return (Yacktman) % | -3.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shandong Jincheng Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,484.879 | ||
| EPS (TTM) (Â¥) | 0.51 | ||
| Beta | 1.36 | ||
| 3-Year Sharpe Ratio | -0.89 | ||
| 3-Year Sortino Ratio | -1.08 | ||
| Volatility % | 44.19 | ||
| 14-Day RSI | 62.86 | ||
| 14-Day ATR (Â¥) | 1.462396 | ||
| 20-Day SMA (Â¥) | 17.1375 | ||
| 12-1 Month Momentum % | -13.43 | ||
| 52-Week Range (Â¥) | 10.65 - 22.98 | ||
| Shares Outstanding (Mil) | 383.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shandong Jincheng Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shandong Jincheng Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shandong Jincheng Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Shandong Jincheng Pharmaceutical Group Co Ltd(SZSE:300233)'s stock price today?
The current price of SZSE:300233 is ¥19.95. The 52 week high of SZSE:300233 is ¥22.98 and 52 week low is ¥10.65.
When is next earnings date of Shandong Jincheng Pharmaceutical Group Co Ltd(SZSE:300233)?
The next earnings date of Shandong Jincheng Pharmaceutical Group Co Ltd(SZSE:300233) is .
Does Shandong Jincheng Pharmaceutical Group Co Ltd(SZSE:300233) pay dividends? If so, how much?
The Dividend Yield %  of Shandong Jincheng Pharmaceutical Group Co Ltd(SZSE:300233) is 1.4% (As of Today), Highest Dividend Payout Ratio of Shandong Jincheng Pharmaceutical Group Co Ltd(SZSE:300233) was 1.47. The lowest was 0.2. And the median was 0.29. The  Forward Dividend Yield % of Shandong Jincheng Pharmaceutical Group Co Ltd(SZSE:300233) is 1.4%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers